Navigation Links
C. difficile vaccine proves safe, 100 percent effective in animal models

An experimental vaccine protected 100 percent of animal models against the highly infectious and virulent bacterium, Clostridium difficile, which causes an intestinal disease that kills approximately 30,000 Americans annually. The research is published ahead of print in Infection and Immunity.

In the study, the vaccine protected the mice and non-human primates against the purified toxins produced by C. difficile, as well as from an orogastric spore infection, a laboratory model that mimics the human disease, after only two immunizations.

"Animals that received two immunizations did not get sick or show signs of C. difficile-associated disease," says corresponding author Michele Kutzler, of Drexel University College of Medicine, Philadelphia.

"While our research was conducted in animal models, the results are very translatable to the clinic," says Kutzler. "In some cases, patients who acquire C. difficile can develop serious complications including severe diarrhea, toxic megacolon, bowel perforation, multi-organ failure, and death. Once fully developed, our DNA vaccine could prevent the deadly effects of C. difficile infection when administered to hospital patients at risk of acquiring C. difficile."

The protection following just two immunizations is especially important since the time window in humans between colonization with C. difficile and the onset of disease symptoms can be a mere 10-14 days, says Kutzler.

The vaccine protects against the bacterial toxins by mustering anti-toxin neutralizing antibodies, says Kutzler.

The cost of fighting the half million C. difficile infections that occur annually in the US is estimated to be nearly $10 billion, most of which could be saved by a successful preventive vaccine, says Kutzler. Morbidity and mortality have risen over the last decade, likely due to increased prevalence of relapsing disease, and hypervirulent strains, she adds.

Treating the disease is especially difficult, as the bacterial spores persist in the hospital environment, where most infections occur. There is no standard, effective treatment for recurrent disease, but a small number of experimental fecal transplants for C. difficile have had a very high success rate, with no adverse reactions.

"Since our vaccine was safe, effective after only two immunizations, and performed exceptionally well, we feel that this success warrants further studies using human patients," says Kutzler.


Contact: Jim Sliwa
American Society for Microbiology

Related biology news :

1. Researchers create vaccine for dust-mite allergies
2. Nasal mucosal inhalation of AD vaccine attenuates Aβ1-42-induced cytotoxicity
3. First positive results toward a therapeutic vaccine against brain cancer
4. Researchers shut down a SARS cloaking system; findings could lead to SARS, MERS vaccines
5. UNL team explores new approach to HIV vaccine
6. Ebola vaccine success highlights dilemma of testing on captive chimps to save wild apes
7. New experimental vaccine produces immune response against MERS virus
8. New technique brings us closer to HIV and Hepatitis C vaccines
9. Potential lung cancer vaccine shows renewed promise
10. Researchers have identified a novel immunological mechanism of great importance for vaccine developm
11. Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
Post Your Comments:
(Date:9/24/2015)... NEW YORK , Sept. 24, 2015  EyeLock ... will be showcasing its award winning and latest technology ... Anaheim, California . EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA.   EyeLock,s platform uses video technology to deliver a ...
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... -- " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ... bn by 2023, expanding at a CAGR of 5.9% during the ... Microbiology Culture Market - Global Industry Analysis, Size, Share, Growth, Trends, ... global microbiology culture market was valued at US$4.51 bn in 2014 ...
(Date:10/13/2015)... N.J. and SAN DIEGO ... and Mast Therapeutics, Inc. have agreed to collaborate in ... excipient-grade poloxamer 188 NF, marketed by BASF under the ... in a variety of pharmaceutical and biological applications, such ... 188 is the starting material for Mast,s lead product ...
(Date:10/13/2015)...  According to Kalorama Information, the global market ... by the end of 2015. Clinical laboratories are ... it is estimated that approximately 80% of physicians, ... addition to diagnosing patients, clinical lab testing may ... drug treatment and conditions, and determine individual therapy. ...
(Date:10/13/2015)... Sunnyvale, CA (PRWEB) , ... October 13, 2015 , ... ... adding key expertise to the company’s fast growing clinical data solutions business. , Jeff ... life science companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex ...
Breaking Biology Technology: